Terms: = Ovarian cancer AND GNA11, GNA-11, 2767, ENSG00000088256
15 results:
1. Caffeic acid phenethyl ester targets ubiquitin-specific protease 8 and synergizes with cisplatin in endometrioid ovarian carcinoma cells.
Colombo D; Gatti L; Sjöstrand L; Carenini N; Costantino M; Corna E; Arrighetti N; Zuccolo M; De Cesare M; Linder S; D'Arcy P; Perego P
Biochem Pharmacol; 2022 Mar; 197():114900. PubMed ID: 34995485
[TBL] [Abstract] [Full Text] [Related]
2. Explore the potential molecular mechanism of polycystic ovarian syndrome by protein-protein interaction network analysis.
Chen Q; Zheng B; Du S; Lin Y
Taiwan J Obstet Gynecol; 2021 Sep; 60(5):807-815. PubMed ID: 34507653
[TBL] [Abstract] [Full Text] [Related]
3. Determination of Potential Therapeutic Targets and Prognostic Markers of ovarian cancer by Bioinformatics Analysis.
Zhang J; Huang S; Quan L; Meng Q; Wang H; Wang J; Chen J
Biomed Res Int; 2021; 2021():8883800. PubMed ID: 33829065
[TBL] [Abstract] [Full Text] [Related]
4. Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer.
Weber-Lassalle N; Borde J; Weber-Lassalle K; Horváth J; Niederacher D; Arnold N; Kaulfuß S; Ernst C; Paul VG; Honisch E; Klaschik K; Volk AE; Kubisch C; Rapp S; Lichey N; Altmüller J; Lepkes L; Pohl-Rescigno E; Thiele H; Nürnberg P; Larsen M; Richters L; Rhiem K; Wappenschmidt B; Engel C; Meindl A; Schmutzler RK; Hahnen E; Hauke J
Breast Cancer Res; 2019 Apr; 21(1):55. PubMed ID: 31036035
[TBL] [Abstract] [Full Text] [Related]
5. Driver pattern identification over the gene co-expression of drug response in ovarian cancer by integrating high throughput genomics data.
Lu X; Lu J; Liao B; Li X; Qian X; Li K
Sci Rep; 2017 Nov; 7(1):16188. PubMed ID: 29170526
[TBL] [Abstract] [Full Text] [Related]
6. FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models.
Corno C; Stucchi S; De Cesare M; Carenini N; Stamatakos S; Ciusani E; Minoli L; Scanziani E; Argueta C; Landesman Y; Zaffaroni N; Gatti L; Perego P
Biochem Pharmacol; 2018 Jan; 147():93-103. PubMed ID: 29155058
[TBL] [Abstract] [Full Text] [Related]
7. Axl molecular targeting counteracts aggressiveness but not platinum-resistance of ovarian carcinoma cells.
Corno C; Gatti L; Arrighetti N; Carenini N; Zaffaroni N; Lanzi C; Perego P
Biochem Pharmacol; 2017 Jul; 136():40-50. PubMed ID: 28404378
[TBL] [Abstract] [Full Text] [Related]
8. Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study.
Soliman PT; Zhang Q; Broaddus RR; Westin SN; Iglesias D; Munsell MF; Schmandt R; Yates M; Ramondetta L; Lu KH
Gynecol Oncol; 2016 Dec; 143(3):466-471. PubMed ID: 27745917
[TBL] [Abstract] [Full Text] [Related]
9. Low molecular weight heparin tinzaparin antagonizes cisplatin resistance of ovarian cancer cells.
Pfankuchen DB; Stölting DP; Schlesinger M; Royer HD; Bendas G
Biochem Pharmacol; 2015 Sep; 97(2):147-57. PubMed ID: 26239805
[TBL] [Abstract] [Full Text] [Related]
10. [Expression of melatonin receptors genes and genes associated with regulation of their activity in endometrial cancer].
Witek A; Jęda A; Baliś M; Orchel J; Sikora B; Skubis A; Szota-Czyż J; Janikowski T; Mazurek U
Ginekol Pol; 2015 Apr; 86(4):248-55. PubMed ID: 26117982
[TBL] [Abstract] [Full Text] [Related]
11. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
[TBL] [Abstract] [Full Text] [Related]
12. Polymorphism of the IL-8 gene and the risk of ovarian cancer.
Koensgen D; Bruennert D; Ungureanu S; Sofroni D; Braicu EI; Sehouli J; Sümnig A; Delogu S; Zygmunt M; Goyal P; Evert M; Olek S; Biebler KE; Mustea A
Cytokine; 2015 Feb; 71(2):334-8. PubMed ID: 25151495
[TBL] [Abstract] [Full Text] [Related]
13. Proportion of gynecologic cancer patients using complementary and alternative medicine.
Supoken A; Chaisrisawatsuk T; Chumworathayi B
Asian Pac J Cancer Prev; 2009; 10(5):779-82. PubMed ID: 20104968
[TBL] [Abstract] [Full Text] [Related]
14. Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts.
Bani MR; Nicoletti MI; Alkharouf NW; Ghilardi C; Petersen D; Erba E; Sausville EA; Liu ET; Giavazzi R
Mol Cancer Ther; 2004 Feb; 3(2):111-21. PubMed ID: 14985451
[TBL] [Abstract] [Full Text] [Related]
15. Combining platinum, paclitaxel and anthracycline in patients with advanced gynaecological malignancy.
Gregory RK; Hill ME; Moore J; A'Hern RP; Johnston SR; Blake P; Shephard J; Barton D; Gore ME
Eur J Cancer; 2000 Mar; 36(4):503-7. PubMed ID: 10717527
[TBL] [Abstract] [Full Text] [Related]
